Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) exert their anti-proliferative activity by interfering with Akt-mTOR signaling and bax:bcl-2 ratio modulation in cells from chronic myeloid leukemic patients

Cancer Science

Volumn 101, Issue 4, 2010, Pages 991-1000

  Di Stefano, Carla ^a   Marfe, Gabriella ^a   Trawinska, Malgorzata Monika ^b   Sinibaldi Salimei, Paola ^a   Silvestri, Romano ^c   Amadori, Sergio ^b   Abruzzese, Elisabetta ^b  

^a Department of Experimental Medicine and Biochemical Sciences ^*  (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NILOTINIB; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PYRROLO[1,2 B][1,2,5]BENZOTHIADIAZEPINE DERIVATIVE; RS 2630; RS 678; RS 779; UNCLASSIFIED DRUG; ADENOSINE DIPHOSPHATE RIBOSE; BENZODIAZEPINE DERIVATIVE; BENZOTHIEPIN DERIVATIVE; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; SULFOXIDE;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DNA FRAGMENTATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MIDDLE AGED;

ADENOSINE DIPHOSPHATE RIBOSE; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BENZODIAZEPINES; BENZOTHIEPINS; CASPASE 9; CYCLIC S-OXIDES; DOWN-REGULATION; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 77957282697     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01490.x     Document Type: Article

References (33)

1. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007; 7: 441-53.
2. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-56.
3. Jacquel A, Herrant M, Legros L et al. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. FASEB J 2003; 17: 2160-2.
4. Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-52.
5. Shah NP, Nicoll JM, Nagar B et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-25.
6. Branford S, Rudzki Z, Walsh S et al. Detection of BCR-ABL mutationsin patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276-83.
7. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 16: 399-401.
8. Lombardo LJ, Lee FY, Chen P et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-61.
9. Druker BJ. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006; 15: 2594-6.
10. Talpaz M, Shah NP, Kantarjian H et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-41.
11. Cortes J, Rousselot P, Kim DW et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207-13.
12. Bradeen HA, Eide CA, O'Hare T et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006; 108: 2332-8.
13. Mughal TI, Goldman JM. Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia. Clin Lymphoma Myeloma 2007; 7 (Suppl 2): S81-4.
14. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008; 1784: 159-85.
15. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J 1997; 16: 3693-704.
16. Joza N, Kroemer G, Penninger JM. Genetic analysis of the mammalian cell death machinery. Trends Genet 2002; 18: 142-9.
17. Budd RC. Activation-induced cell death. Curr Opin Immunol 2001; 13: 356-62.
18. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999; 59 (7 Suppl): 1693s-700s.
19. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997; 15 (Pt1): 1-16.
20. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-65.
21. Communal C, Sumandea M, de Tombe P, Narula J, Solaro RJ, Hajjar RJ. Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci USA 2002; 99: 6252-6.
22. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-19.
23. Marfe G, Di Stefano C, Silvestri R et al. Pyrrolo[1, 2-b][1, 2, 5]benzothiadiazepines (PBTDs) induce apoptosis in K562 cells. BMC Cancer 2007; 7: 207.
24. Silvestri R, Marfè G, Artico M et al. Pyrrolo[1, 2-b][1, 2, 5]benzothiadiazepines (PBTDs): a new class of agents with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and who were imatinib-resistant. J Med Chem 2006; 49: 5840-4.
25. Soverini S, Martinelli G, Rosti G et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23: 4100-41009.
26. Herrmann M, Lorenz HM, Voll R, Grünke M, Woith W, Kalden JR. A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res 1994; 22: 5506-7.
27. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997; 275: 1132-6.
28. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157: 1415-30.
29. Chang HY, Yang X. Proteases for cell suicide: functions and regulation of caspases. Microbiol Mol Biol Rev 2000; 64: 821-46.
30. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer therapy. Exp Cell Res 2000; 256: 42-9.
31. Sartorius UA, Krammer PH. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 2002; 97: 584-92.
32. Rintelen F, Stocker H, Thomas G, Hafen E. PDK1 regulates growththrough Akt and S6K in Drosophila. Proc Natl Acad Sci USA 2001; 98: 15020-5.
33. Kharas MG, Fruman DA. ABL oncogenes and phosphoinositide3-kinase: mechanism of activation and downstream effectors. Cancer Res 2005; 65: 2047-53.